Wellness company Medifast (NYSE:MED) will be reporting earnings this Monday afternoon. Here’s what you need to know.
Medifast missed analysts’ revenue expectations by 0.6% last quarter, reporting revenues of $115.7 million, down 33.8% year on year. It was a mixed quarter for the company, with a solid beat of analysts’ EPS estimates but revenue guidance for next quarter missing analysts’ expectations significantly.
Is Medifast a buy or sell going into earnings? Read our full analysis here, it’s free.
This quarter, analysts are expecting Medifast’s revenue to decline 39.6% year on year to $101.8 million, improving from the 43.1% decrease it recorded in the same quarter last year. Adjusted loss is expected to come in at -$0.19 per share.
Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Medifast has missed Wall Street’s revenue estimates twice over the last two years.
Looking at Medifast’s peers in the consumer staples segment, some have already reported their Q2 results, giving us a hint as to what we can expect. USANA delivered year-on-year revenue growth of 10.8%, beating analysts’ expectations by 4.7%, and Nature's Sunshine reported revenues up 3.8%, topping estimates by 2.2%. USANA traded up 12.4% following the results while Nature's Sunshine was also up 13.7%.
Read our full analysis of USANA’s results here and Nature's Sunshine’s results here.
Debates over possible tariffs and corporate tax adjustments have raised questions about economic stability in 2025. While some of the consumer staples stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 2.4% on average over the last month. Medifast is down 6.1% during the same time and is heading into earnings with an average analyst price target of $15 (compared to the current share price of $13.75).
Unless you’ve been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story.
StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.